Javascript must be enabled to continue!
Glucocorticoids as prophylaxis against acute mountain sickness
View through CrossRef
SummaryObjective Acute mountain sickness (AMS) characterized by presence of symptoms including headache, nausea, excessive fatigue, loss of appetite, irritability and insomnia is a major impediment to work performance in human subjects who are rapidly inducted to high altitude (HA) during the initial phase of induction. The present study aims at to evaluate the efficacy of prophylactic administration of low dose glucocorticoids in prevention of AMS in normal healthy men who are inducted to HA by air.Design Fifty healthy men were randomly divided into five groups of 10 each. Group I received prednisolone (Pred) 10 mg, Group II Pred 20 mg, Group III Pred 40 mg, Group IV dexamethasone 0·5 mg, Group V received placebo once a day in the morning for 2 days at sea level (SL) and for 3 days on arrival at an altitude of 3450 m by air.Measurements The severity of AMS was assessed using Lake Louise AMS scoring system. Physiological parameters like blood pressure, respiratory rate, peripheral blood O2 saturation and heart rate were measured at sea level and on arrival at HA. Circulatory levels of cortisol and adrenocorticotropic hormone (ACTH) were measured by radioimmunoassay (RIA) and immunoradiometreic assay (IRMA), respectively.Results In the placebo group, significant AMS could be detected at 12 h of arrival at HA, peaked by day 1 or 2 of stay and started declining thereafter. As compared to the placebo group, the steroid treated groups showed a significant (P < 0·01) reduction in daily AMS score. When compared with prednisolone 10 mg, 40 mg and dexamethasone groups, the prednisolone 20 mg group showed an optimal response in reduction of AMS symptoms. The O2 saturation showed a significant decline (P < 0·001) on arrival at HA, but the pattern of O2 saturation in placebo and glucocorticoid groups was identical. Similarly, the rise in heart rate and blood pressure and on day 3 of stay at HA was similar in placebo and glucocorticoid‐treated groups. An increase in plasma cortisol in placebo group was observed on day 3 of stay at HA and continued to rise till day 8 of observations. The cortisol levels in Pred 10 mg and Pred 20 mg groups on day 1 and 3 of arrival at HA were not significantly different than the SL post‐treatment values but were found to be significantly higher on day 8 of stay. Plasma cortisol in Pred 40 mg and dexamethasone groups was significantly lower (P < 0·01) on day 1 and 3 of stay but showed an increase by day 8 of stay. The ACTH levels were increased at HA in placebo group but did not show any significant change till day 3 of stay in steroid treated subjects and were found to be higher in all groups on day 8 of observations.Conclusion These observations suggest that administration of low‐dose glucocorticoids can curtail acute mountain sickness significantly without influencing the normal adreno cortical response to hypoxia.
Title: Glucocorticoids as prophylaxis against acute mountain sickness
Description:
SummaryObjective Acute mountain sickness (AMS) characterized by presence of symptoms including headache, nausea, excessive fatigue, loss of appetite, irritability and insomnia is a major impediment to work performance in human subjects who are rapidly inducted to high altitude (HA) during the initial phase of induction.
The present study aims at to evaluate the efficacy of prophylactic administration of low dose glucocorticoids in prevention of AMS in normal healthy men who are inducted to HA by air.
Design Fifty healthy men were randomly divided into five groups of 10 each.
Group I received prednisolone (Pred) 10 mg, Group II Pred 20 mg, Group III Pred 40 mg, Group IV dexamethasone 0·5 mg, Group V received placebo once a day in the morning for 2 days at sea level (SL) and for 3 days on arrival at an altitude of 3450 m by air.
Measurements The severity of AMS was assessed using Lake Louise AMS scoring system.
Physiological parameters like blood pressure, respiratory rate, peripheral blood O2 saturation and heart rate were measured at sea level and on arrival at HA.
Circulatory levels of cortisol and adrenocorticotropic hormone (ACTH) were measured by radioimmunoassay (RIA) and immunoradiometreic assay (IRMA), respectively.
Results In the placebo group, significant AMS could be detected at 12 h of arrival at HA, peaked by day 1 or 2 of stay and started declining thereafter.
As compared to the placebo group, the steroid treated groups showed a significant (P < 0·01) reduction in daily AMS score.
When compared with prednisolone 10 mg, 40 mg and dexamethasone groups, the prednisolone 20 mg group showed an optimal response in reduction of AMS symptoms.
The O2 saturation showed a significant decline (P < 0·001) on arrival at HA, but the pattern of O2 saturation in placebo and glucocorticoid groups was identical.
Similarly, the rise in heart rate and blood pressure and on day 3 of stay at HA was similar in placebo and glucocorticoid‐treated groups.
An increase in plasma cortisol in placebo group was observed on day 3 of stay at HA and continued to rise till day 8 of observations.
The cortisol levels in Pred 10 mg and Pred 20 mg groups on day 1 and 3 of arrival at HA were not significantly different than the SL post‐treatment values but were found to be significantly higher on day 8 of stay.
Plasma cortisol in Pred 40 mg and dexamethasone groups was significantly lower (P < 0·01) on day 1 and 3 of stay but showed an increase by day 8 of stay.
The ACTH levels were increased at HA in placebo group but did not show any significant change till day 3 of stay in steroid treated subjects and were found to be higher in all groups on day 8 of observations.
Conclusion These observations suggest that administration of low‐dose glucocorticoids can curtail acute mountain sickness significantly without influencing the normal adreno cortical response to hypoxia.
Related Results
Prevalence of acute mountain sickness in the Swiss Alps.
Prevalence of acute mountain sickness in the Swiss Alps.
OBJECTIVE--To assess the prevalence of symptoms and signs of acute mountain sickness of the Swiss Alps. DESIGN--A study using an interview and clinical examination in a representat...
Comparison of Standard Versus Intermediate Prophylaxis Dose for Venous Thromboembolism Prophylaxis in Patients Hospitalized With COVID-19 Infection
Comparison of Standard Versus Intermediate Prophylaxis Dose for Venous Thromboembolism Prophylaxis in Patients Hospitalized With COVID-19 Infection
Background: COVID-19 infection is associated with a high risk of venous thromboembolism (VTE) events. VTE prophylaxis reduces the risk of these events. The optimal dose of VTE prop...
Hubungan Tingkat Kebugaran Jasmani dengan Aklimatisasi Pendaki Gunung
Hubungan Tingkat Kebugaran Jasmani dengan Aklimatisasi Pendaki Gunung
The This study aims to prove the relationship between the level of physical fitness towards the acclimatization of mountain climbers in the sireum sukabumi dampal nature lovers com...
Simulated descent v dexamethasone in treatment of acute mountain sickness: a randomised trial
Simulated descent v dexamethasone in treatment of acute mountain sickness: a randomised trial
Abstract
Objective
: Evaluation and comparison of the therapeutic efficacy of a portable hyperbaric chamber and dexametha...
Modeling the impacts of influenza antiviral prophylaxis strategies in nursing homes
Modeling the impacts of influenza antiviral prophylaxis strategies in nursing homes
Background: Antiviral chemoprophylaxis for influenza is recommended in nursing homes to prevent transmission and severe disease among residents with higher risk of severe influenza...
Quality of Postoperative Venous Thromboembolism Prophylaxis in Neuro-oncologic Surgery
Quality of Postoperative Venous Thromboembolism Prophylaxis in Neuro-oncologic Surgery
Abstract
BACKGROUND: Given the vagaries of published guidelines and the lack of high-quality evidence on the method, timing, and dose of venou...
Adherence to antiemetic prophylaxis guidelines and the association with nausea/vomiting occurrence in breast cancer patients undergoing chemotherapy
Adherence to antiemetic prophylaxis guidelines and the association with nausea/vomiting occurrence in breast cancer patients undergoing chemotherapy
This study aimed to examine the level of adherence to chemotherapy-induced nausea and vomiting (CINV) prophylaxis guidelines and its association with CINV occurrence at K Hospital....
Prophylaxis in the haemophilia population
Prophylaxis in the haemophilia population
Summary. Prophylaxis is recommended as preventive therapy for young boys with severe haemophilia in countries where safe factor concentrates are available. This recommendation is ...

